1. Search Result
Search Result
Isoforms Recommended: CDK1
Results for "

Cdk-1

" in MedChemExpress (MCE) Product Catalog:

143

Inhibitors & Agonists

2

Peptides

8

Natural
Products

8

Recombinant Proteins

3

Isotope-Labeled Compounds

5

Antibodies

3

Click Chemistry

3

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-168673

    CDK Cancer
    CDK1-IN-6 (Ligand 3) is a potent CDK1 inhibitor. CDK1-IN-6 has the potential for the research of cancer [1].
    CDK1-IN-6
  • HY-115924

    CDK Cancer
    CDK1-IN-1 is a potent CDK1 inhibitor (CDK1/CycB IC50=161.2 nM) with potential antiproliferative activity and selectivity for cancer tissues. CDK1-IN-1 induces apoptosis in p53 dependent manner through the intrinsic apoptotic pathway. CDK1-IN-1 is a potential targeted antitumor agent [1].
    CDK1-IN-1
  • HY-112463

    CDK Cancer
    CDK1-IN-2 is a CDK1 inhibitor (IC50: 5.8 μM) [1].
    CDK1-IN-2
  • HY-112462

    CDK Cancer
    Cdk1/2 Inhibitor III is a selective Cdk1/2 inhibitor, with an IC50 of 2.1 μM for CDK1/cyclin B [1].
    Cdk1/2 Inhibitor III
  • HY-RS02349

    Small Interfering RNA (siRNA) CDK Others

    Cdk1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cdk1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Cdk1 Mouse Pre-designed siRNA Set A
    Cdk1 Mouse Pre-designed siRNA Set A
  • HY-RS02350

    Small Interfering RNA (siRNA) CDK Others

    Cdk1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Cdk1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Cdk1 Rat Pre-designed siRNA Set A
    Cdk1 Rat Pre-designed siRNA Set A
  • HY-RS02348

    Small Interfering RNA (siRNA) CDK Others

    CDK1 Human Pre-designed siRNA Set A contains three designed siRNAs for CDK1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    CDK1 Human Pre-designed siRNA Set A
    CDK1 Human Pre-designed siRNA Set A
  • HY-151409

    CDK Cancer
    CDK1-IN-5 (10h) is a selective CDK1 inhibitor with IC50s of 42.19, 188.71 and 354.15 nM for CDK1, CDK2 and CDK5, respectively. CDK1-IN-5 inhibits growth of cancer cells by affecting cell cycle. CDK1-IN-5 can be used for the research of cancer [1].
    CDK1-IN-5
  • HY-151407

    CDK Cancer
    CDK1-IN-3 (8g) is a selective CDK1 inhibitor with IC50s of 36.8, 305.17 and 369.37 nM for CDK1, CDK2 and CDK5, respectively. CDK1-IN-3 inhibits the growth of cancer cells by affecting cell cycle. CDK1-IN-3 can be used for the research of cancer [1].
    CDK1-IN-3
  • HY-151408

    CDK Cancer
    CDK1-IN-4 (10d) is a selective CDK1 inhibitor with IC50s of 44.52, 624.93 and 135.22 nM for CDK1, CDK2 and CDK5, respectively. CDK1-IN4 inhibits the growth of cancer cells by affecting cell cycle. CDK1-IN-4 can be used for the research of cancer [1].
    CDK1-IN-4
  • HY-147646

    CDK Apoptosis Cancer
    CDK1/Cyc B-IN-1 (Compound 5) is a selective CDK1/Cyc B complex inhibitor with an IC50 of 97 nM. CDK1/Cyc B-IN-1 triggers apoptosis and G2/M cell cycle arrest. CDK1/Cyc B-IN-1 shows broad-spectrum cytotoxic action against cancer cell lines [1].
    CDK1/Cyc B-IN-1
  • HY-146253

    CDK Apoptosis Bcl-2 Family Caspase Cancer
    CDK1/2/4-IN-1 (compound 3a) is a potent CDK inhibitor with IC50 values of 1.47, 0.78 and 0.87 μM for CDK1, CDK2 and CDK4, respectively. CDK1/2/4-IN-1 arrests cell cycle at G2/M phase and induces apoptosis. CDK1/2/4-IN-1 elevates Bax, caspase-3, P53 levels and decreases Bcl-2 level. CDK1/2/4-IN-1 can be used for cancer research [1].
    CDK1/2/4-IN-1
  • HY-47733

    CDK Cancer
    WAY-643018 (Compound 2), an indazolecarboxamide derivative, is a CDK1, CDK2, and CDK4 inhibitor. CDK1/2/4-IN-2 has the potential for cancer research [1].
    CDK1/2/4-IN-2
  • HY-147901

    Histone Demethylase CDK Apoptosis Caspase Cancer
    KDM1/CDK1-IN-1 (compound 4) is a potent KDM1 and CDK1 inhibitor, with IC50 values of 0.096 and 0.078 μM, respectively.KDM1/CDK1-IN-1 induces cell cycle arrest at G2/M phase and apoptosis in HOP-92 cells. KDM1/CDK1-IN-1 exhibits potent cytotoxic activity against the CCRF-CEM, HOP-92 and Hep-G2 cells, with IC50 values of 16.34, 3.45 and 7.79 μM, respectively [1].
    KDM1/CDK1-IN-1
  • HY-12529
    Ro-3306
    40+ Cited Publications

    CDK Apoptosis Cancer
    Ro-3306 is a potent and selective inhibitor of CDK1, with Kis of 20 nM, 35 nM and 340 nM for CDK1, CDK1/cyclin B1 and CDK2/cyclin E, respectively.
    Ro-3306
  • HY-144637

    Apoptosis Autophagy Cancer
    Autophagy inducer 2 (Compound 11i) is a potent autophagy inducer. Autophagy inducer 2 exhibits apparent antiproliferative activity against the MCF-7 cell line with an IC50 value of 1.31 μM and remarkably inhibits the colony formation of the MCF-7 cells. Autophagy inducer 2 arrests the MCF-7 cells in the G2/M phase by regulating the cell-cycle-related proteins Cdk-1 and Cyclin B1. Autophagy inducer 2 has the potential for the research of breast cancer [1].
    Autophagy inducer 2
  • HY-137432B
    Avotaciclib hydrochloride
    2 Publications Verification

    BEY1107 hydrochloride

    CDK Cancer
    Avotaciclib hydrochloride is the hydrochloride form of Avotaciclib (HY-137432), a CDK1 inhibitor. Avotaciclib hydrochloride can be used for a few specific cancers, such as pancreatic cancer, in which CDK1 is abnormal and strongly expressed [1].
    Avotaciclib hydrochloride
  • HY-15569

    CDK Cancer
    NU6102 is a potent CDK1 and CDK2 inhibitor with IC50s of 9.5 nM and 5.4 nM for CDK1/cyclinB and CDK2/cyclinA3, respectively. NU6102 shows selectivity for CDK1/CDK2 over CDK4 (IC50 of 1.6 μM), DYRK1A (IC50 of 0.9 μM), PDK1 (IC50 of 0.8 μM) and ROCKII (IC50 of 0.6 μM) [1] .
    NU6102
  • HY-10329
    JNJ-7706621
    2 Publications Verification

    Aurora Kinase CDK Apoptosis Cancer
    JNJ-7706621 is a potent aurora kinase inhibitor, and also inhibits CDK1 and CDK2, with IC50s of 9 nM, 3 nM, 11 nM, and 15 nM for CDK1, CDK2, aurora-A and aurora-B, respectively [1] .
    JNJ-7706621
  • HY-112394

    GSK-3 CDK Cancer
    2-Cyanoethylalsterpaullone (compound 7) is an Alsterpaullone (HY-108359) derivative, which exhibits potent and selective inhibitory activities against CDK1/Cyclin B and GSK-3β (GSK-3β: IC50=0.8 nM; CDK1/Cyclin B: IC50=0.23 nM) [1].
    2-Cyanoethylalsterpaullone
  • HY-118310

    CDK Cancer
    Xylocydine is an inhibitor of CDK1/2, inhibiting CDK function in various apoptotic processes. Xylocydine specifically blocks CDK1 and CDK2 activity with IC50 of 1.4 nM and 61 nM, respectively. In addition, Xylocydine downregulates phosphorylated nucleolin and retinoblastoma protein levels. [1].
    Xylocydine
  • HY-103221

    Aryl Hydrocarbon Receptor GSK-3 CDK Others
    MeBIO is a potent AhR (aryl hydrocarbon receptor) agonist, with IC50 of 44 μM (GSK-3) and 55 μM (CDK1/cyclin B), respectively [1].
    MeBIO
  • HY-10580
    GSK 3 Inhibitor IX
    10+ Cited Publications

    6-Bromoindirubin-3'-oxime; BIO; MLS 2052

    GSK-3 CDK Apoptosis Cancer
    GSK 3 Inhibitor IX (6-Bromoindirubin-3'-oxime; BIO) is a potent, selective, reversible and ATP-competitive inhibitor of GSK-3α/β and CDK1-cyclinB complex with IC50s of 5 nM/320 nM/80 nM for (GSK-3α/β)/CDK1/CDK5, respectively.
    GSK 3 Inhibitor IX
  • HY-103647

    CDK VEGFR GSK-3 Cancer
    K00546 is a potent CDK1 and CDK2 inhibitor with IC50s of 0.6 nM and 0.5 nM for CDK1/cyclin B and CDK2/cyclin A, respectively. K00546 is also a potent CDC2-like kinase 1 (CLK1) and CLK3 inhibitor with IC50s of 8.9 nM and 29.2 nM, respectively [1] .
    K00546
  • HY-103381

    CDK GSK-3 Cancer
    NSC693868 is a selective inhibitor of CDK1 and CDK5 with IC50s of 600 nM and 400 nM, respectively. NSC693868 less potently inhibits GSK3β with an IC50 of 1 µM) and does not block CDC25 activity. NSC693868 is used to help define the roles of CDK1 and CDK5 in various signaling pathways [1].
    NSC693868
  • HY-114779

    CDK Cancer
    N9-Isopropylolomoucine is a mitotic cyclin dependent kinase (CDK) inhibitor. N9-Isopropylolomoucine targets CCNB 1/CDK1 and can be used for cancer research [1].
    N9-Isopropylolomoucine
  • HY-P2480

    CDK Others
    Histone H1-derived Peptide is a phosphopeptide and the peptide substrates containes a sequence in accordance with the optimal recognition motif for CDK, can be used to detecting CDK1-cyclinB1 enzyme activity [1] .
    Histone H1-derived Peptide
  • HY-170306

    CDK Cancer
    LZ9 is a ATP-competitive CDK1 and CDK2 inhibitor. LZ9 has the potential for the research of colorectal cancer (CRC) [1] .
    LZ9
  • HY-P5428

    CDK Others
    Cdc2 kinase substrate is a biological active peptide. (The native peptide HATPPKKKRK is a substrate for cyclin-dependent protein kinase 1 (CDC2; CDK1).)
    Cdc2 kinase substrate
  • HY-10005
    Flavopiridol
    40+ Cited Publications

    HMR-1275; Alvocidib; L86-8275

    CDK Autophagy HIV Apoptosis Cancer
    Flavopiridol (Alvocidib) is a broad spectrum and competitive inhibitor of CDKs, inhibiting CDK1, CDK2, CDK4 with IC50s of 30, 170, 100 nM, respectively.
    Flavopiridol
  • HY-168519

    STAT Cancer
    STAT3-IN-36 (compound 11g) is a triple-target inhibitor targeting LRPPRC, STAT3, and CDK1 with anticancer activity. STAT3-IN-36 binds to LRPPRC, STAT3, and CDK1, exerting a stronger anticancer effect than TMF (HY-N6818) or Capecitabine (HY-B0016). STAT3-IN-36 inhibits HGC27 cells with IC50 1.8 μM. [1].
    STAT3-IN-36
  • HY-18629
    SU9516
    4 Publications Verification

    CDK Autophagy Apoptosis Cancer
    SU9516 is a potent CDK2 inhibitor, with an IC50 of 22 nM, and also shows inhibitory effects on CDK1 and CDK4, with IC50s of 40, 200 nM, respectively.
    SU9516
  • HY-10006
    Flavopiridol Hydrochloride
    40+ Cited Publications

    Alvocidib Hydrochloride; L86-8275 Hydrochloride; HMR-1275 Hydrochloride

    CDK Autophagy HIV Cancer
    Flavopiridol Hydrochloride (Alvocidib Hydrochloride) is a broad inhibitor of CDK, competing with ATP to inhibit CDKs including CDK1, CDK2, CDK4 with IC50s of 30, 170, 100 nM, respectively.
    Flavopiridol Hydrochloride
  • HY-137432A
    Avotaciclib trihydrochloride
    2 Publications Verification

    BEY1107 trihydrochloride

    CDK Cancer
    Avotaciclib (BEY1107) trihydrochloride is a potent and orally active inhibitor of cyclin dependent kinase 1 (CDK1). Avotaciclib trihydrochloride can be used for the research of locally advanced or metastatic pancreatic cancer [1].
    Avotaciclib trihydrochloride
  • HY-15241

    LCQ-195; AT9311

    CDK Cancer
    NVP-LCQ195 (AT9311; LCQ195) is a small molecule heterocyclic inhibitor of CDK1, CDK2, CDK3 and CDK5 with IC50 of 1-42 nM.
    NVP-LCQ195
  • HY-137432
    Avotaciclib
    2 Publications Verification

    BEY1107

    CDK Cancer
    Avotaciclib (BEY1107) is a potent and orally active inhibitor of cyclin dependent kinase 1 (CDK1). Avotaciclib can be used for the research of locally advanced or metastatic pancreatic cancer [1].
    Avotaciclib
  • HY-10492
    Dinaciclib
    45+ Cited Publications

    SCH 727965

    CDK Apoptosis Cancer
    Dinaciclib (SCH 727965) is a potent inhibitor of CDK, with IC50s of 1 nM, 1 nM, 3 nM, and 4 nM for CDK2, CDK5, CDK1, and CDK9, respectively [1].
    Dinaciclib
  • HY-119715

    CDK Apoptosis Cancer
    AG-012986 is a multitargeted CDK inhibitor. AG-012986 is active against CDK1/2/4/6/5/9, with Kis of 9.2 nM (CDK4/cyclin), 94 nM (CDK2/cyclin A), and 44 nM (CDK1/cyclin B), IC50s of 4 nM (CDK9/cyclin T) and 22 nM (CDK5/p35). AG-012986 has antiproliferative activities against cancer cells. AG-012986 induces cell cycle arrest, and apoptosis [1].
    AG-012986
  • HY-117535
    CDK2-IN-4
    2 Publications Verification

    CDK Cancer
    CDK2-IN-4 (compound 73) is a potent and selective CDK2 inhibitor with an IC50 of 44 nM for CDK2/cyclin A, shows 2,000-fold selectivity over CDK1/cyclin B (IC50=86 uM) [1].
    CDK2-IN-4
  • HY-112336

    CDK GSK-3 Neurological Disease
    Aloisine RP106 (compound 38) is a potent inhibitor of Cdk1/cyclin B, Cdk5/p25, and GSK3 with IC50s of 0.70µM, 1.5µM, 0.92 µM, respectively [1].
    Aloisine RP106
  • HY-13266A
    BS-181 hydrochloride
    4 Publications Verification

    CDK Cancer
    BS-181 hydrochloride is a highly selective CDK7 inhibitor with IC50 of 21 nM, and > 40-fold selective for CDK7 than CDK1, 2, 4, 5, 6, or 9.
    BS-181 hydrochloride
  • HY-10014
    R547
    2 Publications Verification

    CDK GSK-3 Apoptosis Cancer
    R547 is a potent, selective and orally active ATP-competitive CDK inhibitor, with Kis of 2 nM, 3 nM and 1 nM for CDK1/cyclin B, CDK2/cyclin E and CDK4/cyclin D1, respectively [1] .
    R547
  • HY-111260

    CDK GSK-3 Apoptosis Cancer
    R547 mesylate is a potent, selective and orally active ATP-competitive CDK inhibitor, with Kis of 2 nM, 3 nM and 1 nM for CDK1/cyclin B, CDK2/cyclin E and CDK4/cyclin D1, respectively [1] .
    R547 mesylate
  • HY-50943
    AT7519 Hydrochloride
    10+ Cited Publications

    CDK Apoptosis Cancer
    AT7519 Hydrochloride is a potent inhibitor of CDKs, with IC50s of 210, 47, 100, 13, 170, and <10 nM for CDK1, CDK2, CDK4 to CDK6, and CDK9, respectively.
    AT7519 Hydrochloride
  • HY-137432D

    BEY1107 sulfate

    CDK Cancer
    Avotaciclib (BEY1107) sulfate is a potent and orally active inhibitor of cyclin dependent kinase 1 (CDK1). Avotaciclib sulfate can be used for the research of locally advanced or metastatic pancreatic cancer [1].
    Avotaciclib sulfate
  • HY-13914

    BAY 1000394

    CDK Cancer
    Roniciclib is an orally bioavailable pan-cyclin dependent kinase (CDK) inhibitor, with IC50s of 5-25 nM for CDK1, CDK2, CDK3, CDK4, CDK7 and CDK9.
    Roniciclib
  • HY-123369

    CDK Apoptosis Cancer
    BMI-1026 is a cyclin-dependent kinase 1 (Cdk1) inhibitor with IC50 of 2.3 nM. BMI-1026 induces apoptosis by arresting the G2-M phase [1].
    BMI-1026
  • HY-15612

    CDK Cancer
    CDK4 inhibitor is a novel and specific CDK4/Cyclin D1 inhibitor with an IC50 of 10 nM; 1500 and 500 fold than CDK1/Cyclin B (IC50>15 uM) and CDK2/Cyclin A (IC50=5.265 uM) respectively.
    CDK4-IN-1
  • HY-111930

    GSK-3 CDK Cancer
    5-Iodo-indirubin-3'-monoxime is a potent GSK-3β, CDK5/P25 and CDK1/cyclin B inhibitor, competing with ATP for binding to the catalytic site of the kinase, with IC50s of 9, 20 and 25 nM, respectively [1].
    5-Iodo-indirubin-3'-monoxime
  • HY-122609

    PF-6808472

    CDK Cancer
    XO44 (PF-6808472) is a broad-spectrum covalent kinase probe. XO44 can bind in CDK2 and CDK1. XO44 also labels CDK4 proteins in cells [1] .
    XO44

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: